Celcuity (CELC) Share-based Compensation (2016 - 2025)
Celcuity (CELC) posted Share-based Compensation of $9.5 million for Q4 2025, up 39.49% on a QoQ basis from $6.8 million in Q3 2025, and up 308.47% year-over-year from $2.3 million in Q4 2024.
Celcuity (CELC) Share-based Compensation (2016 - 2025) Analysis & Trends
Celcuity's Share-based Compensation history runs 10 years deep, the most recent figure standing at $9.5 million for Q4 2025.
- Quarterly Share-based Compensation rose 308.47% year-over-year to $9.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.4 million (up 206.0% YoY) and the FY2025 annual result came in at $21.4 million, up 206.0% from the prior year.
- Share-based Compensation was $9.5 million for Q4 2025 at Celcuity, up from $6.8 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $9.5 million in Q4 2025 and bottomed at $449098.0 in Q1 2021.
- A 5-year average of $2.1 million and a median of $1.3 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation declined 15.96% — and 2025, when it surged 308.47%.
- Celcuity's Share-based Compensation stood at $699916.0 in 2021, then soared by 62.79% to $1.1 million in 2022, then grew by 9.05% to $1.2 million in 2023, then soared by 86.31% to $2.3 million in 2024, then jumped by 308.47% to $9.5 million in 2025.
- Business Quant data shows CELC's Share-based Compensation at $9.5 million in Q4 2025, $6.8 million in Q3 2025, and $2.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Celcuity | 4.13 Bn | 4.13 Bn | - | 9.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.46 Mn |
| Dec 31, 2025 | 9.46 Mn |
| Sep 30, 2025 | 6.78 Mn |
| Sep 30, 2025 | 6.78 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.44 Mn |
| Mar 31, 2025 | 2.44 Mn |
| Dec 31, 2024 | 2.32 Mn |
| Dec 31, 2024 | 2.32 Mn |
| Sep 30, 2024 | 1.93 Mn |
| Sep 30, 2024 | 1.93 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.33 Mn |
| Mar 31, 2024 | 1.33 Mn |
| Dec 31, 2023 | 1.24 Mn |
| Dec 31, 2023 | 1.24 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.11 Mn |